Molecular evolution of human immunodeficiency virus env in humans and monkeys: Similar patterns occur during natural disease progression or rapid virus passage

Journal of Virology

Volumn 76, Issue 10, 2002, Pages 5278-5284

  Hofmann Lehmann, Regina ^a   Vlasak, Josef ^a   Chenine, Agnés Laurence ^a   Li, Pei Lin ^a   Baba, Timothy W ^a   Montefiori, David C ^a   McClure, Harold M ^a   Anderson, Daniel C ^a   Ruprecht, Ruth M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; DISEASE COURSE; DISEASE MODEL; GENE MUTATION; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MOLECULAR EVOLUTION; MORTALITY; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RHESUS MONKEY; SEQUENCE ANALYSIS; T LYMPHOCYTE; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; EVOLUTION, MOLECULAR; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE ALIGNMENT; VIRAL ENVELOPE PROTEINS;

EID: 0036237397     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.10.5278-5284.2002     Document Type: Article

References (50)

1. Mucosal infection of neonatal rhesus monkeys with cell-free SIV
2. Human neutralizing monoclonal antibodies of the IgGI subtype protect against mucosal simian-human immunodeficiency virus infection
3. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization
4. Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course
5. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
6. Immunization with recombinant canarypox vectors expressing membrane-anchored gp120 followed by soluble gp160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
7. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein
8. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2)
9. Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo
10. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
11. SIV/HIV-1 chimeric viruses having HIV-1 env gene: A new animal model and a candidate for attenuated live vaccine
12. Conserved N-linked oligosaccharides of the C-terminal portion of human immunodeficiency virus type 1 gp120 and viral susceptibility to neutralizing antibodies
13. Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: Comparison of one- vs. two-enzyme systems
14. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB gp120 peptide RP135
15. Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques
16. + T cells and AIDS in pig-tailed macaques
17. + lymphocyte depletion in rhesus monkeys
18. Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection
19. + by triple and quadruple combinations of human monoclonal antibodies and hightiter anti-human immunodeficiency virus type 1 immunoglobulins
20. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins
21. Persistent infection of macaques with simian-human immunodeficiency viruses
22. Viremia and AIDS in rhesus macaques after intramuscular inoculation of plasmid DNA encoding full-length SIVmac239
23. KU-2 that causes AIDS neurological disease, and renal disease in rhesus macaques
24. Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS
25. Utility of SHIV for testing HIV-1 vaccine candidates in macaques
26. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV)
27. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120
28. KU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques
29. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques
30. Effect of changes in the glycosylation of the human immunodeficiency virus type 1 envelope on the immunoreactivity and sensitivity to thrombin of its third variable domain
31. Neuropathogenesis of chimeric simian/human immunodeficiency virus infection in pig-tailed and rhesus macaques
32. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
33. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
34. Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses
35. A role for carbohydrates in immune evasion in AIDS
36. Oral transmission of primate lentiviruses
37. Escape of HIV-1 is associated with lack of V3 domain-specific antibodies in vivo
38. Loss of antibody reactivity directed against the V3 domain of certain human immunodeficiency virus type 1 variants during disease progression
39. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain
40. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing
41. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys
42. KU inoculated into immunized macaques caused infection, but virus burdens progressively declined with time
43. Initial characterization of viral sequences from a SHIV-inoculated pig-tailed macaque that developed AIDS
44. mac and HIV-1 regions of the genome and has altered cytotropism
45. KU-1
46. Effect of amino acid changes in the VIN2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody
47. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: Role of glycosylation in the correct folding of the V1/V2 domain
48. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding
49. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions
50. Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo